FDA Emergency Use Authorization (EUA): How It Works

The FDA Emergency Use Authorization (EUA) is a legal mechanism under 21 U.S.C. § 564 that allows the Food and Drug Administration to authorize unapproved medical products — or unapproved uses of approved products — for use during declared public health emergencies. This page explains the statutory basis, procedural mechanics, classification boundaries, and key tensions that define how EUAs function in practice. Understanding EUA authority is essential for manufacturers, healthcare institutions, and policymakers navigating emergency response frameworks.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

An Emergency Use Authorization grants temporary authority for medical products to be distributed and used before full FDA approval or clearance has been granted. The statutory basis is Section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), codified at 21 U.S.C. § 564. The mechanism applies to drugs, biologics, devices, and in vitro diagnostics.

The scope of EUA authority is deliberately broad. It covers four product categories: drugs and biologics regulated by the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), and medical devices and diagnostics regulated by the Center for Devices and Radiological Health (CDRH). It also extends to combination products and, through separate provisions, to certain countermeasures under the Project BioShield Act of 2004 (Public Law 108-276).

EUAs are distinct from standard FDA approval pathways in one critical dimension: they require a substantially lower evidentiary threshold. The statutory standard is "may be effective" rather than the "substantial evidence" standard required for full approval. However, authorization can only proceed when FDA concludes that the known and potential benefits outweigh the known and potential risks of the product.

Geographic and temporal scope is bounded by the underlying emergency declaration. An EUA remains in effect until the declaration is terminated, the authorization is revoked, or the product receives full approval or clearance — whichever occurs first.

Core mechanics or structure

Three prerequisite conditions must all be satisfied before FDA can issue an EUA (21 U.S.C. § 564(b)(1)):

1. The Secretary of HHS must have declared a public health emergency under Section 319 of the Public Health Service Act, or the Secretary of Defense must have determined there is a military emergency, or the Secretary of HHS must have declared a significant potential for such an emergency.
2. FDA must determine that a serious or life-threatening disease or condition exists.
3. There must be no adequate, approved, and available alternative to the product being authorized.

Once these conditions are met, an EUA request — submitted by a manufacturer, government agency, or other sponsor — undergoes FDA review. The review is structured around four scientific and regulatory determinations:

• Efficacy: Whether available data support a conclusion that the product "may be effective."
• Risk-benefit: Whether known and potential benefits outweigh known and potential risks.
• Information availability: Whether healthcare providers and recipients can access adequate information to make informed decisions.
• Conditions of authorization: What labeling, distribution controls, and reporting requirements will apply.

FDA publishes the complete authorization letter, the fact sheet for healthcare providers, and the fact sheet for recipients — all of which carry legal force as conditions of the EUA. Manufacturers must comply with post-authorization reporting requirements specified in each individual EUA letter, which typically include adverse event reporting aligned with FDA's MedWatch system.

Causal relationships or drivers

The EUA mechanism is triggered by a cascade of formal government actions, not by product readiness or manufacturer request alone. The causal chain begins with an emergency declaration at the Secretary of HHS level, which opens the statutory pathway. FDA's authority does not activate until that declaration is in place.

Demand-side drivers — such as a novel pathogen with high transmission and mortality — create pressure to move faster than the standard FDA clinical trials oversight timeline allows. The COVID-19 pandemic illustrated this dynamic at scale: FDA issued the first EUA for an mRNA vaccine on December 11, 2020 (FDA News Release, December 11, 2020), after approximately 11 months of accelerated Phase 3 trial data accumulation rather than the typical multi-year timeline.

Supply-side drivers include the availability of pre-clinical and early-phase clinical data, manufacturing readiness, and regulatory dossier completeness. Sponsors can engage in pre-EUA meetings with FDA, analogous to pre-NDA meetings under the FDA New Drug Application process, to align on data expectations before formal submission.

The public health emergency framework intersects with the medical countermeasure ecosystem managed by the Biomedical Advanced Research and Development Authority (BARDA) and the Strategic National Stockpile, meaning EUA requests for government-procured countermeasures often involve multi-agency coordination.

Classification boundaries

EUA authority is frequently confused with related but legally distinct FDA mechanisms. The following boundaries define what an EUA is and is not:

EUA vs. Investigational New Drug (IND): An IND allows clinical testing of an unapproved product; it does not authorize commercial distribution or routine clinical use. An EUA authorizes actual deployment outside a controlled trial setting.

EUA vs. Accelerated Approval: Accelerated Approval is a permanent approval pathway for serious conditions using surrogate endpoints, with post-marketing confirmatory trial requirements. Accelerated Approval results in full legal marketing authorization; an EUA does not.

EUA vs. Expanded Access (Compassionate Use): Expanded access authorizes individual patients or small cohorts to access unapproved products outside trials. EUA is a population-level authorization.

EUA vs. 510(k) Clearance: FDA 510(k) clearance is a permanent device pathway based on substantial equivalence to a predicate device. Emergency Use Authorization for devices bypasses the 510(k) process entirely and does not confer the same regulatory status.

EUA vs. De Novo: The De Novo device pathway creates a new device classification and a permanent authorization. EUA authorization for a device is temporary and does not create classification precedent.

Tradeoffs and tensions

The EUA framework embodies a fundamental regulatory tension: the tradeoff between speed and evidentiary certainty. The "may be effective" standard enables faster deployment but means authorization can be granted on Phase 2 data, interim Phase 3 data, or observational evidence that would be insufficient for standard approval.

This tradeoff generates at least 3 distinct operational tensions:

Autonomy vs. mandate: EUA conditions have historically required that recipients be informed of their right to refuse (per 21 U.S.C. § 564(e)(1)(A)(ii)(III)), but public health mandates from employers, schools, or government entities operate under different legal authority — creating tension between federal EUA conditions and state or institutional mandates.

Liability protection vs. accountability: Products used under EUA are generally shielded from liability under the Public Readiness and Emergency Preparedness (PREP) Act (42 U.S.C. § 247d-6d), except in cases of willful misconduct. This protection accelerates manufacturer participation but limits victim recourse.

Revocation risk: FDA retains authority to revoke an EUA if conditions no longer meet the statutory criteria — including if an adequate alternative becomes available. This creates market uncertainty for manufacturers who invest in EUA-authorized products, since full approval via the FDA Biologics License Application process is required for long-term market continuity.

Common misconceptions

Misconception: EUA approval is the same as full FDA approval.
Correction: An EUA is not an approval. The product has not met the "substantial evidence" standard of effectiveness required under 21 U.S.C. § 355 for drugs or the safety and effectiveness standard under 21 U.S.C. § 360e for devices. The authorization is conditional, temporary, and tied to the emergency declaration.

Misconception: EUA products have not been tested.
Correction: FDA's statutory requirement is that available evidence supports a "may be effective" conclusion. For COVID-19 vaccines, Phase 3 trials enrolled 30,000 to 44,000 participants each before EUA submission (FDA Vaccines and Related Biological Products Advisory Committee Briefing Documents, 2020). The question is not whether testing occurred, but whether it has reached the evidentiary threshold for full approval.

Misconception: An EUA automatically expires when the pandemic ends.
Correction: EUA termination requires a formal revocation action by FDA or an official termination of the underlying emergency declaration. An EUA does not expire automatically on a calendar date; it remains legally operative until FDA acts.

Misconception: Any manufacturer can request an EUA for any product.
Correction: Requests can come from manufacturers, government agencies (including the Department of Defense and HHS), or other entities, but must be accompanied by a complete regulatory package. FDA exercises independent scientific judgment and has declined or deferred EUA requests where data were insufficient.

Checklist or steps (non-advisory)

The following sequence describes the procedural stages of an EUA as defined in FDA guidance (FDA EUA Guidance Documents):

Stage 1 — Declaration
- Secretary of HHS issues a public health emergency declaration under Section 319 of the Public Health Service Act, or
- A determination of military emergency is made, or
- A determination of significant potential for emergency is issued.

Stage 2 — FDA Determination
- FDA determines a serious or life-threatening condition exists.
- FDA confirms no adequate approved alternative is available.

Stage 3 — Sponsor Submission
- Sponsor submits an EUA request including pre-clinical data, clinical data (if available), manufacturing information, and proposed labeling.
- Sponsor may have completed a pre-EUA meeting with relevant FDA center (CDER, CBER, or CDRH).

Stage 4 — FDA Scientific Review
- FDA reviews efficacy data against the "may be effective" standard.
- FDA conducts independent risk-benefit analysis.
- FDA determines conditions of authorization (labeling, distribution controls, reporting requirements).

Stage 5 — Authorization Issuance
- FDA issues EUA letter specifying authorized use, populations, conditions, and required fact sheets.
- Healthcare provider fact sheet and recipient fact sheet are finalized and published.

Stage 6 — Post-Authorization Monitoring
- Sponsor submits adverse event and safety reports per conditions in the EUA letter.
- FDA monitors post-authorization data and may revise conditions, restrict distribution, or revoke authorization.

Stage 7 — Termination or Transition
- EUA is revoked by FDA, emergency declaration is terminated, or product receives full approval/clearance.
- For drugs and biologics transitioning to full approval, a complete BLA or NDA submission is required.

Reference table or matrix

The FDA's broader public health emergency response infrastructure — including pre-positioned regulatory frameworks, standing guidance documents, and inter-agency agreements — provides the operational context within which individual EUAs are processed. For a complete picture of how FDA's authority is structured across all its regulatory domains, the FDA Authority overview provides foundational framing.